Acute lymphoblastic leukemia (ALL) is a rare but aggressive blood cancer that begins in the bone marrow and affects white blood cells called lymphocytes. It’s the most common childhood cancer, with about 4,000 of the 6,000 U.S. cases each year occurring in children.
While ALL is serious, treatment can often lead to a cure. But for patients with relapsed or hard-to-treat B-cell ALL, options remain limited.
A new international study led by MD Anderson Cancer Center tested blinatumomab — an immunotherapy that trains the immune system to attack leukemia cells — in an easier injection form instead of a continuous 28-day infusion.
The results were striking: more than 75% of patients went into remission, with manageable side effects.
As study lead Elias Jabbour, M.D., noted: “This could be transformative once assessed in the frontline setting.”
Click here to learn more about Acute Lymphoblastic Leukemia (ALL)
Copyright © 2025 CMedEd.com
